Market Capitalization (Millions $) |
4,809 |
Shares
Outstanding (Millions) |
95 |
Employees |
1,276 |
Revenues (TTM) (Millions $) |
523 |
Net Income (TTM) (Millions $) |
-559 |
Cash Flow (TTM) (Millions $) |
82 |
Capital Exp. (TTM) (Millions $) |
21 |
Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for the treatment of rare and ultra-rare genetic diseases. The company's mission is to provide novel treatments for these rare diseases where there is unmet medical need.
The company was founded in 2010 by Emil Kakkis, who is a pioneer in the field of rare diseases. Ultragenyx started as a small startup and has grown to become one of the leading rare disease biotech companies in the industry. It is headquartered in Novato, California, USA, and has operations in Europe as well.
Ultragenyx is known for its expertise in developing and commercializing rare disease therapies. The company has a robust pipeline of programs that are aimed at addressing a range of rare diseases. Some of the key therapeutic areas the company is focused on include metabolic disorders, skeletal disorders, neurological disorders, and immunology.
One of the company's top products is Mepsevii (vestronidase alfa), which is an enzyme replacement therapy for the treatment of a rare genetic disorder called mucopolysaccharidosis VII (MPS VII). This condition is caused by a deficiency in beta-glucuronidase, which leads to the accumulation of certain complex sugars in the body tissues and organs. Mepsevii works by replacing the missing enzyme in the patient's body, thereby reducing the accumulation of complex sugars and improving the patient's symptoms.
Another product under development by Ultragenyx is DTX301, a gene therapy product for the treatment of ornithine transcarbamylase (OTC) deficiency. OTC deficiency is a rare genetic disorder that affects the body's ability to break down ammonia, leading to its build-up in the blood and tissues. DTX301 works by introducing a healthy copy of the OTC gene into the patient's liver cells, which helps to restore the body's ability to break down ammonia.
Ultragenyx has a strong commitment to research and innovation, and it is constantly exploring new approaches to treat rare diseases. The company has a team of highly experienced professionals who are dedicated to bringing innovative medicines to patients with rare diseases. It has also established partnerships with other companies and organizations in the industry to advance its research and development programs.
In summary, Ultragenyx Pharmaceutical Inc is a biopharmaceutical company that is dedicated to the development and commercialization of innovative therapies for the treatment of rare and ultra-rare genetic diseases. The company has a broad pipeline of rare disease programs, and it is committed to advancing its research and development efforts to bring new treatments to patients in need.
Company Address: 60 Leveroni Court Novato 94949 CA
Company Phone Number: 483-8800 Stock Exchange / Ticker: NASDAQ RARE
|